KymetaTM Expands Its Next Generation Solutions with Commercial Availability of the u8 GOV Terminal and u8 GO
9.2.2021 17:00:00 EET | Business Wire | Press release
Kymeta (www.kymetacorp.com)—the communications company making mobile global—announced today the expansion and availability of its KymetaTM u8 product, including the Kymeta u8 GOV terminal with an embedded iDirect 950mp modem and the u8 GO transportable terminal. Kymeta u8 GOV terminals are designed to meet the needs of government, military and specialized commercial use and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005134/en/
The u8 GOV terminal and u8 GO provide the complete connectivity solution for on-the-go communications. (Photo: Business Wire)
The u8 GOV terminal includes a FIPS, 140-2 level 3 TRANSEC module and meets the demands of tactical users in scenarios that require secure data, voice, and video connectivity in highly mobile military, government and other rapid response applications. The u8 GOV terminal covers the full Ku-band and is available today as a turnkey terminal with a satellite modem, cellular modem, and SD-WAN capabilities. It is compliant with existing security requirements as defined by the National Institute of Standards and Technology (NIST).
“Kymeta’s solutions meet the mission-critical needs of military, first responders, and commercial customers providing ‘always-on’ connectivity for mobile platforms, making communications on the move more seamless and reliable than ever,” said Rob Weitendorf, Vice President, Business Development, Kymeta.
Also available today, the u8 GO transportable terminals come in multiple configurations including ODU, Commercial and GOV terminals, and enable safe transport with a hardened and rugged shipping case for protection and provide a built-in vehicle mount to support easy communications on the pause (COTP) and communications on-the-move (COTM). This transportable configuration is easily maneuverable and ideal for rapid deployments and has been tested against military transportation standards including MIL-STD-810H, Transit Drop, Transportation Shock, and Loose Cargo Vibration. The u8 GO includes an outdoor AC/DC power supply, supports communications on the pause (COTP) with a 25-degree tilt mechanism, and can also be mounted on a vehicle for easy deployment in a multitude of use cases.
The Kymeta u8 solutions, which now also include the u8 GOV terminal and u8 GO transportable case, provide a complete connectivity solution for communications-on-the-move (COTM) and networks-on-the-move (NOTM) when and where you need it most. The u8 terminal, with Kymeta’s revolutionary software-defined, electronic beam-steering technology, is low profile and easy-to-mount on vehicles and vessels. The u8 turnkey solutions come in multiple terminal configurations that provide customers with the hardware, software, and connectivity they need.
Kymeta recently launched its next-generation antenna, terminal, and services in Q4 of 2020, and has received an overwhelmingly positive response from the industry. The Kymeta u8 terminal paired with Kymeta’s hybrid satellite-cellular connectivity services, Kymeta Connect™, transforms the purchase and consumption of mobile data with all-inclusive hardware, connectivity, and services monthly subscription. The Kymeta u8 is the world’s only commercially available flat-panel electronically steered antenna built specifically for mobility and designed for the needs of military, first responders, and commercial customers.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005134/en/
Contact information
Business Inquiries for Kymeta:
Jon Maron
Vice President of Marketing and Communications
Kymeta Corporation
+1 425.658.8827
jmaron@kymetacorp.com
Media Inquiries for Kymeta:
Amanda Barry
Associated Director PR, The Summit Group
abarry@summitslc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom